DEVELOPMENT OF A COMMERCIAL POINT-OF-CARE DEVICE CAPABLE OF ELECTRONICALLY SENSI

这项提议的长期目标是开发一种能够电子感应癌症患者外周血中单个循环肿瘤细胞(CTC)的商业护理点设备。病毒载体是一个纳米技术平台，代表着一项重大的技术进步。它包含一个基于电极的生物传感器，可以为高灵敏度的临床点诊断提供一种廉价的格式。该病毒融合了一个由丝状噬菌体颗粒组成的生物亲和层，其中每个颗粒可以显示与特定癌细胞表面标记的多个配体。这种格式最大限度地提高了特异性和亲和力，同时最大限度地减少了生物污垢。该病毒包括一个灵敏的区域检测器，能够检测个位数或更低的NM浓度的生物标记物。我们的技术目标是构建检测前列腺癌CTC S的病毒载体。我们的目标标记物包括PSA、PSMA、PSCA和整合蛋白3。病毒载体将被优化，用于识别和实时电检测前列腺癌细胞，这些细胞在生物相关的液体基质中表达目标标记。

The long term goal of this proposal is the development of a commercial point-of-care device capable of electronically sensing single circulating tumor cells (CTC) in the peripheral blood of a cancer patient. The viratrode is a nanotechnology platform that represents a significant technological advance. It contains an electrode-based biosensor and can provide an inexpensive format for point-of-care diagnosis with high sensitivity. The viratrode incorporates a bioaffinity layer consisting of a ¿kelp forest¿ of filamentous phage particles, in which each particle can display multiple ligands to a particular cancer cell surface marker. This format maximizes specificity and affinity, while minimizing biofouling. The viratrode incorporates a sensitive area detector capable of detecting single digit or lower nM concentrations of biomarkers. Our Technical Objectives focus on constructing viratrodes for detecting prostate cancer CTC¿s. Our target markers include PSA, PSMA, PSCA, and vβ3 intergrins. The viratrodes will be optimized for the recognition and real-time electrical detection of prostate cancer cells that express the target markers in a biologically relevant fluid matrix.